MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 573454 | Name: (S)-Apomorphine Hydrochloride

Description:

WARNING: This product is for research use only, not for human or veterinary use.

(S)-Apomorphine Hydrochloride is a Dopamine (D1 and D2) receptor agonist which may be effective in the treatment of Parkinson's disease. This product is not available (it is or may be a DEA-controlled substance).

Chemical Structure

(S)-Apomorphine Hydrochloride
(S)-Apomorphine Hydrochloride
CAS#41035-30-7 (S-isomer HCl)

Theoretical Analysis

MedKoo Cat#: 573454

Name: (S)-Apomorphine Hydrochloride

CAS#: 41035-30-7 (S-isomer HCl)

Chemical Formula: C17H18ClNO2

Exact Mass: 303.1026

Molecular Weight: 303.79

Elemental Analysis: C, 67.21; H, 5.97; Cl, 11.67; N, 4.61; O, 10.53

Price and Availability

Size Price Availability Quantity
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
58-00-4 (free base) 314-19-2 (HCl) 41372-20-7 (HCl hydrate) 41035-30-7 (S-isomer HCl) 39478-62-1 (S-isomer)
Synonym
(S)-Apomorphine Hydrochloride; APL-130277; APL 130277; APL130277;
IUPAC/Chemical Name
(S)-5,6,6a,7-Tetrahydro-6-methyl- 4H-dibenzo[de,g]quinoline-10,11-diol Hydrochloride
InChi Key
SKYZYDSNJIOXRL-ZOWNYOTGSA-N
InChi Code
InChI=1S/C17H17NO2.ClH/c1-18-8-7-10-3-2-4-12-15(10)13(18)9-11-5-6-14(19)17(20)16(11)12;/h2-6,13,19-20H,7-9H2,1H3;1H/t13-;/m0./s1
SMILES Code
OC1=CC=C2C(C3=C4C(CCN(C)[C@@]4([H])C2)=CC=C3)=C1O.[H]Cl
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 303.79 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Davis PJ, Seyhan S, Soine W, Smith RV. Convenient synthesis of (S)-(+)-apomorphine from (R)-(-)-apomorphine. J Pharm Sci. 1980 Sep;69(9):1056-8. doi: 10.1002/jps.2600690918. PMID: 7411407. 1: Jenner P, Katzenschlager R. Apomorphine - pharmacological properties and clinical trials in Parkinson's disease. Parkinsonism Relat Disord. 2016 Dec;33 Suppl 1:S13-S21. doi: 10.1016/j.parkreldis.2016.12.003. Epub 2016 Dec 13. Review. PubMed PMID: 27979722. 2: Hauser RA, Olanow CW, Dzyngel B, Bilbault T, Shill H, Isaacson S, Dubow J, Agro A. Sublingual apomorphine (APL-130277) for the acute conversion of OFF to ON in Parkinson's disease. Mov Disord. 2016 Sep;31(9):1366-72. doi: 10.1002/mds.26697. Epub 2016 Jul 19. PubMed PMID: 27430123. 3: Trenkwalder C, Chaudhuri KR, García Ruiz PJ, LeWitt P, Katzenschlager R, Sixel-Döring F, Henriksen T, Sesar Á, Poewe W; Expert Consensus Group for Use of Apomorphine in Parkinson's Disease, Baker M, Ceballos-Baumann A, Deuschl G, Drapier S, Ebersbach G, Evans A, Fernandez H, Isaacson S, van Laar T, Lees A, Lewis S, Martínez Castrillo JC, Martinez-Martin P, Odin P, O'Sullivan J, Tagaris G, Wenzel K. Expert Consensus Group report on the use of apomorphine in the treatment of Parkinson's disease--Clinical practice recommendations. Parkinsonism Relat Disord. 2015 Sep;21(9):1023-30. doi: 10.1016/j.parkreldis.2015.06.012. Epub 2015 Jun 17. Review. PubMed PMID: 26189414. 4: Unti E, Ceravolo R, Bonuccelli U. Apomorphine hydrochloride for the treatment of Parkinson's disease. Expert Rev Neurother. 2015;15(7):723-32. doi: 10.1586/14737175.2015.1051468. Epub 2015 Jun 2. Review. PubMed PMID: 26037961. 5: Watanabe Y, Nakamura Y, Cao X, Ohara H, Yamazaki Y, Murayama N, Sugiyama Y, Izumi-Nakaseko H, Ando K, Yamazaki H, Sugiyama A. Intravenous Administration of Apomorphine Does NOT Induce Long QT Syndrome: Experimental Evidence from In Vivo Canine Models. Basic Clin Pharmacol Toxicol. 2015 Jun;116(6):468-75. doi: 10.1111/bcpt.12343. Epub 2014 Nov 22. PubMed PMID: 25370785.